142 related articles for article (PubMed ID: 30449214)
21. Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/T-cell lymphoma.
Li L; Zhang C; Zhang L; Li X; Wu JJ; Sun ZC; Fu XR; Wang XH; Chang Y; Wang R; Qiu YJ; Zhang MZ
Neoplasma; 2014; 61(2):225-32. PubMed ID: 24299319
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
Wang JH; Wang L; Liu CC; Xia ZJ; Huang HQ; Lin TY; Jiang WQ; Lu Y
Oncotarget; 2016 May; 7(20):29092-101. PubMed ID: 27093153
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.
Chaubard S; Marouf A; Lavergne D; Lemonnier F; Rossignol J; Clavert A; Gressin R; Cartron G; Waultier-Rascalou A; Vargaftig J; Salles G; Bachy E; Ghesquières H; Tournilhac O; Chauchet A; Le Gouill S; Damaj G; Fornecker LM; Sibon D; Obéric L; Michot JM; Gaulard P; Hermine O; Couronné L; Jaccard A
Br J Haematol; 2023 May; 201(4):673-681. PubMed ID: 36799516
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma.
Wang JH; Wang H; Wang YJ; Xia ZJ; Huang HQ; Jiang WQ; Lu Y
Oncotarget; 2016 Jun; 7(23):35412-22. PubMed ID: 27072578
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
Jaccard A; Gachard N; Marin B; Rogez S; Audrain M; Suarez F; Tilly H; Morschhauser F; Thieblemont C; Ysebaert L; Devidas A; Petit B; de Leval L; Gaulard P; Feuillard J; Bordessoule D; Hermine O;
Blood; 2011 Feb; 117(6):1834-9. PubMed ID: 21123825
[TBL] [Abstract][Full Text] [Related]
26. A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type.
Ji J; Liu T; Xiang B; Liu W; He C; Chen X; Li J; Chang H; Dai Y; Dong T
Leuk Lymphoma; 2014 Dec; 55(12):2955-7. PubMed ID: 24679007
[No Abstract] [Full Text] [Related]
27. [Analysis of Clinical Efficacy and Influencing Factors of Gemcitabine-L-Asparaginase-Oxaliplatin Chemotherapy Scheme and Radiotherapy for Treatment of Early ENKTL Patients].
Qiu C; Wang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1420-1425. PubMed ID: 29070118
[TBL] [Abstract][Full Text] [Related]
28. Extra-nodal natural killer/T cell lymphoma in elderly patients: the impact of aging on clinical outcomes and treatment tolerability.
Kim SM; Park S; Oh DR; Ahn YC; Ko YH; Kim SJ; Kim WS
Ann Hematol; 2016 Mar; 95(4):581-91. PubMed ID: 26729202
[TBL] [Abstract][Full Text] [Related]
29. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.
Wang L; Wang ZH; Chen XQ; Li YJ; Wang KF; Xia YF; Xia ZJ
Cancer; 2013 Jan; 119(2):348-55. PubMed ID: 22811078
[TBL] [Abstract][Full Text] [Related]
30. [Analysis of prognostic factors of extranodal NK/T-cell lymphoma treated with pegaspargase/L-asparaginase: a multicenter retrospective study].
Shen ZY; Chen XC; Shan HR; Jia T; Gu WY; Wang F; Teng QL; Wang L; Wang CL; Shi YY; Zhang H; Miao YQ; Zhu TG; Ji CY; Ye JJ; Zhang MZ; Zhang XD; Wang L; Xu KL; Sang W
Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):642-648. PubMed ID: 37803837
[No Abstract] [Full Text] [Related]
31. [A multi-center retrospective study of L-asparaginase-based regimens as first-line treatment in newly diagnosed extranodal NK/T-cell lymphoma].
Yuan F; Wei X; Yin Q; Li Y; Mi R; Ai H; Yang H; Li H; Ge S; Liu Y; Song Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):614-8. PubMed ID: 25052604
[TBL] [Abstract][Full Text] [Related]
32. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia.
Suzuki R
Int J Hematol; 2010 Dec; 92(5):697-701. PubMed ID: 21116747
[TBL] [Abstract][Full Text] [Related]
33. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.
Kim SJ; Yang DH; Kim JS; Kwak JY; Eom HS; Hong DS; Won JH; Lee JH; Yoon DH; Cho J; Nam TK; Lee SW; Ahn YC; Suh C; Kim WS
Ann Hematol; 2014 Nov; 93(11):1895-901. PubMed ID: 24947798
[TBL] [Abstract][Full Text] [Related]
34. High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study.
Ding H; Chang J; Liu LG; Hu D; Zhang WH; Yan Y; Ma LY; Li ZC; Ma YJ; Hao SG; Tao R
Int J Hematol; 2015 Aug; 102(2):181-7. PubMed ID: 25997870
[TBL] [Abstract][Full Text] [Related]
35. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.
Ito Y; Kimura H; Maeda Y; Hashimoto C; Ishida F; Izutsu K; Fukushima N; Isobe Y; Takizawa J; Hasegawa Y; Kobayashi H; Okamura S; Kobayashi H; Yamaguchi M; Suzumiya J; Hyo R; Nakamura S; Kawa K; Oshimi K; Suzuki R
Clin Cancer Res; 2012 Aug; 18(15):4183-90. PubMed ID: 22675173
[TBL] [Abstract][Full Text] [Related]
36. Ki-67 Can Predict the Response to the Gemcitabine, Oxaliplatin And L-asparaginase Regimen (GELOX) and Prognosis in Patients with Nasal Natural Killer/T-cell Lymphoma.
Zhang J; Jiang W; Wang WD; Liu CC; Hu YP; Xia ZJ
Asian Pac J Cancer Prev; 2015; 16(11):4515-20. PubMed ID: 26107196
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type.
Kim HJ; Ock CY; Kim TM; Lee SH; Lee JY; Jung SH; Cho YS; Kim M; Keam B; Kim DW; Kim IH; Heo DS
Cancer Res Treat; 2018 Jul; 50(3):670-680. PubMed ID: 28675023
[TBL] [Abstract][Full Text] [Related]
38. Clinical study of l-asparaginase in the treatment of extranodal NK/T-cell lymphoma, nasal type.
Yong W
Hematol Oncol; 2016 Jun; 34(2):61-8. PubMed ID: 25899032
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.
Wei W; Wu P; Li L; Zhang ZH
Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702
[TBL] [Abstract][Full Text] [Related]
40. Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T-cell lymphoma: A randomized, controlled, open-label, multicenter study.
Zhang L; Wang Y; Li X; Li L; Wang X; Sun Z; Wu J; Fu X; Zhang X; Yu H; Wang G; Chang Y; Yan J; Zhou Z; Wu X; Nan F; Li W; Zhang M
Int J Cancer; 2021 Mar; 148(6):1470-1477. PubMed ID: 33034052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]